Nitric acid

Bedfont Scientific Ltd receives FDA clearance for NObreath® FeNO monitor

Retrieved on: 
月曜日, 1月 31, 2022
Online, Diagnosis, Patient, Online and offline, ATS, Food, MAIDSTONE, Critical Care Medicine (journal), Internet, National Centre for Disease Control, Healthcare Professionals for Healthcare Reform, Bedfont, Nitric acid, Inflammation, Asthma, ERS, Center, American Journal of Respiratory and Critical Care Medicine, CDC, Taylor & Francis, Eosinophilic, Allergy, Nitric oxide, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Multimedia, Medical device, Explosive

MAIDSTONE, England, Jan. 31, 2022 /PRNewswire/ -- UK, med-tech company, Bedfont Scientific Ltd., is celebrating a brighter 2022 as the U.S. Food and Drug Administration (FDA) cleared its NObreath FeNO monitor for use in monitoring airway inflammation.

Key Points: 
  • MAIDSTONE, England, Jan. 31, 2022 /PRNewswire/ -- UK, med-tech company, Bedfont Scientific Ltd., is celebrating a brighter 2022 as the U.S. Food and Drug Administration (FDA) cleared its NObreath FeNO monitor for use in monitoring airway inflammation.
  • The NObreath, which conforms to ATS and ERS guidelines1, is a portable, non-invasive device for the measurement of Fractional Exhaled Nitric Oxide (FeNO) in human breath.
  • The NObreath works by measuring FeNO through breath analysis, making the process quick, simple, and non-invasive for both the Healthcare Professional and the patient.
  • We are one step closer to achieving our purpose; to make FeNO monitoring lower cost and therefore more accessible globally.

Grammer Professional Driver selected to America's Road Team Captains

Retrieved on: 
木曜日, 1月 20, 2022
Education, Atlas, Knowledge, Safety, Liquefied petroleum gas, Glossary of the American trucking industry, Nitric acid, American Trucking Associations, Talent, Solution, Leadership, Legislative Affairs Office, Owner-operator, Industry, Company, Tata Chemicals, Senior, Transport, Warehouse, Management, Risk, Ammonia

COLUMBUS, Ind., Jan. 20, 2022 /PRNewswire/ --Grammer Logistics ( www.grammerlogistics.com ) ("Grammer" or the "Company"), a leading chemicals, industrial gases and hazardous materials transportation and logistics firm, announced today that professional driver James Ellis has been selected as a 2022-2023 America's Road Team Captain, through the American Trucking Association ( www.ata.com ).

Key Points: 
  • COLUMBUS, Ind., Jan. 20, 2022 /PRNewswire/ --Grammer Logistics ( www.grammerlogistics.com ) ("Grammer" or the "Company"), a leading chemicals, industrial gases and hazardous materials transportation and logistics firm, announced today that professional driver James Ellis has been selected as a 2022-2023 America's Road Team Captain, through the American Trucking Association ( www.ata.com ).
  • James Ellis was selected as one of only 22 professional truck drivers in the nation.
  • "James Ellis is a shining example of a professional driver, and we are extremely proud of him for being selected to this position of leadership.
  • Grammer Logistics ( www.grammerlogistics.com ) is recognized as the premier provider of safe, dependable bulk hazardous chemicals transportation services in the United States.

TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA

Retrieved on: 
木曜日, 1月 13, 2022
Biomarker, Medicine, Ageing, SOC, Patient, Vaccine, Incidence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Population, Excipient, Adult, NASDAQ, Program, Rash, TSLP, Helminthiasis, Back pain, Disease, Placentalia, Amgen, Birth, Asthma, Acute exacerbation of chronic obstructive pulmonary disease, Standard of care, Pharyngitis, Pregnancy, AstraZeneca, ICS, Allergic conjunctivitis, Fetus, Caregiver, Miscarriage, Nitric acid, Arthralgia, Food, AMGN, Infection, Hypersensitivity, FDA, Maintenance, Cell, Physician, Pharmaceutical industry, Dietary supplement, Health insurance

The Tezspire Together Program offers provider and patient product resources and support, including information related to coverage, reimbursement and distribution.

Key Points: 
  • The Tezspire Together Program offers provider and patient product resources and support, including information related to coverage, reimbursement and distribution.
  • TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma

Retrieved on: 
木曜日, 1月 13, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Biomarker, Medicine, Ageing, SOC, OCS, Patient, III, Mortality, Vaccine, Inflammation, Incidence, Population, Excipient, Adult, Program, Rash, Back pain, TSLP, Helminthiasis, Safety, Disease, Placentalia, Birth, Asthma, Acute exacerbation of chronic obstructive pulmonary disease, Standard of care, Pharyngitis, Pregnancy, AstraZeneca, Phenotype, Allergic conjunctivitis, Fetus, Caregiver, Quality of life, Miscarriage, Nitric acid, Allergy, US Foods, Arthralgia, Risk, Food, Hospital, Immunology, Phase, Infection, Hypersensitivity, FDA, Maintenance, Senior, Pharmaceutical industry, Health insurance, Amgen

With TEZSPIRE now available, this important new treatment has the potential to transform care for a broad population of patients living with severe asthma.

Key Points: 
  • With TEZSPIRE now available, this important new treatment has the potential to transform care for a broad population of patients living with severe asthma.
  • TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.
  • The management of severe asthma: economic analysis of the cost of treatments for severe asthma.

Grammer Logistics Opens Operations Terminal in Houston

Retrieved on: 
月曜日, 1月 10, 2022
Tata Chemicals, Atlas, Safety, Transport, Liquefied petroleum gas, Solution, Gulf Coast of the United States, Growth, Owner-operator, Company, Nitric acid, Warehouse, Rail freight transport, Greater Houston, Ammonia

COLUMBUS, Ind., Jan. 10, 2022 /PRNewswire/ --Grammer Logistics ( www.grammerlogistics.com ) ("Grammer" or the "Company"), a leading chemicals, industrial gases and hazardous materials transportation and logistics firm, announced today that it has opened a new operations terminal in the Greater Houston area.

Key Points: 
  • COLUMBUS, Ind., Jan. 10, 2022 /PRNewswire/ --Grammer Logistics ( www.grammerlogistics.com ) ("Grammer" or the "Company"), a leading chemicals, industrial gases and hazardous materials transportation and logistics firm, announced today that it has opened a new operations terminal in the Greater Houston area.
  • The terminal will serve as a logistics center for Grammer's operations and driver teams in the market, supporting the company's strategic commitment to the Gulf Coast region.
  • The opening of this new terminal comes one month after Grammer opened a commercial headquarters in Houston.
  • With more than 20 terminal locations across the United States, Grammer Logistics specializes in safe and reliable logistics solutions across various chemical market segments.

Africa Mining Chemicals Market Trends Analysis & Forecasts, 2021-2028 by Ore Type (Iron Ore, Powder Gold, Phosphate), & Application (Explosives & Drilling, Mineral Processing) - ResearchAndMarkets.com

Retrieved on: 
火曜日, 12月 21, 2021
Chemicals, Plastics, Natural Resources, Manufacturing, Mining, Minerals, Nitric acid, Mining, Mineral, Uranium, Environment, Health, Explosive, USD, Mercury, United Nations, Printing, Marketing, Gold, Medicine, CAGR, Risk, Country, Metal, Industry, Uncertainty, Mineral processing, Copper, Lead, Growth, First Nations in Ontario, Silver, Phosphate

The "Africa Mining Chemicals Market Size, Share & Trends Analysis Report By Ore Type (Iron Ore, Powder Gold, Phosphate), By Application (Explosives & Drilling, Mineral Processing), By Country, And Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Africa Mining Chemicals Market Size, Share & Trends Analysis Report By Ore Type (Iron Ore, Powder Gold, Phosphate), By Application (Explosives & Drilling, Mineral Processing), By Country, And Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Africa mining chemicals market size is expected to reach USD 960.97 million by 2028 and is expected to expand at a CAGR of 5.6% from 2021 to 2028.
  • Factors such as the rising demand for minerals, increasing mining activities, and water treatment are likely to fuel the market growth over the forecast period.
  • This growth is attributed to the growing gold mining activities in the country
    Africa Mining Chemicals Market Variables, Trends & Scope

DGAP-News: sterna biologicals announces dosing of first patient in phase IIa proof-of-concept study with SB010 in moderate to severe asthma

Retrieved on: 
月曜日, 12月 20, 2021
Nitric acid, Hope, Global Initiative, Company, IIA, Hospital, Epigenetics of diabetes Type 2, LABA, The New England Journal of Medicine, Sterna, POC, Today, Pulmonology, Pharmacokinetics, Clinic, ICS, Inhalation, Safety, Inflammation, Patient, Global Initiative for Asthma, Ulcerative colitis, Hannover Medical School, Factor X, GINA, COPD, Bronchospasm, Atopic dermatitis, Immunomodulation, Chronic obstructive pulmonary disease, In Practice Systems Limited, Asthma, Deoxyribozyme, Gesellschaft mit beschränkter Haftung, Aquaculture, Pharmaceutical industry

"We are pleased that the first patient has been treated in our GIANT-1 trial with inhaled SB010 in patients with uncontrolled moderate to severe asthma," said Dr. Marion Wencker, Chief Medical Officer of sterna biologicals.

Key Points: 
  • "We are pleased that the first patient has been treated in our GIANT-1 trial with inhaled SB010 in patients with uncontrolled moderate to severe asthma," said Dr. Marion Wencker, Chief Medical Officer of sterna biologicals.
  • "I am excited about the potential SB010 holds in treating patients with moderate to severe uncontrolled asthma.
  • In this study, sterna will for the first time, combine pharmacological and digital therapy by integrating VisionHealth's Kata(R) Clinical into the trial.
  • Consequently, the Company's therapeutic candidates containing hgd40, SB010 and SB012, address several inflammatory processes simultaneously and rebalance an overall dysregulated immune response.

TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma

Retrieved on: 
金曜日, 12月 17, 2021
FDA, Health, Clinical Trials, Research, Pharmaceutical, Science, Standard of care, Allergic conjunctivitis, Pharyngitis, Population, SOC, TSLP, Risk, Inflammation, Disease, Patient, Placentalia, OCS, FDA, Physician, Adult, Biomarker, Incidence, Allergy, Royal Brompton Hospital, Vaccine, Hospital, Safety, Pregnancy, Quality of life, Program, Amgen, Asthma, News, Nitric acid, US Foods, Back pain, Arthralgia, CEO, Infection, Medicine, Rash, Multimedia, Miscarriage, Birth, Phase, Food, Severe cutaneous adverse reactions, Mene Pangalos, Fetus, III, AstraZeneca, Hypersensitivity, Biopharmaceutical, Caregiver, Phenotype, The New England Journal of Medicine, Mortality, Ageing, Priority review, Maintenance, Acute exacerbation of chronic obstructive pulmonary disease, Excipient, Helminthiasis, Pharmaceutical industry, Medical device, EU

TEZSPIRE represents a much-needed new treatment for the many patients who remain underserved and continue to struggle with severe, uncontrolled asthma.

Key Points: 
  • TEZSPIRE represents a much-needed new treatment for the many patients who remain underserved and continue to struggle with severe, uncontrolled asthma.
  • TEZSPIRE is a first-in-class medicine indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.
  • The management of severe asthma: economic analysis of the cost of treatments for severe asthma.

FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA

Retrieved on: 
金曜日, 12月 17, 2021
Standard of care, Allergic conjunctivitis, Pharyngitis, Population, SOC, TSLP, NASDAQ, Risk, Inflammation, Disease, Patient, Placentalia, Press release, FDA, Physician, Adult, Biomarker, Incidence, Royal Brompton Hospital, Vaccine, Hospital, Safety, Pregnancy, Quality of life, Program, Amgen, Asthma, News, Nitric acid, Cell, Back pain, AAN, Arthralgia, ICS, Infection, Medicine, Rash, Upper respiratory tract infection, Miscarriage, Birth, Food, Fetus, Allergy, AstraZeneca, Hypersensitivity, Caregiver, AMGN, The New England Journal of Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ageing, Priority review, Maintenance, Common, Acute exacerbation of chronic obstructive pulmonary disease, Excipient, Helminthiasis, Pharmaceutical industry, Dietary supplement, Research, EU

"Tezspire represents a much-needed new treatment for the many patients who remain underserved and continue to struggle with severe, uncontrolled asthma."

Key Points: 
  • "Tezspire represents a much-needed new treatment for the many patients who remain underserved and continue to struggle with severe, uncontrolled asthma."
  • "For the first time, many people living with severe asthma have the opportunity to receive treatment regardless of the cause of their inflammation."
  • Tezspireis a first-in-class medicine indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

Grammer Logistics Opens Commercial HQ in Houston

Retrieved on: 
月曜日, 12月 6, 2021
Heart, Owner-operator, Atlas, Nitric acid, Safety, Grammer, Solution, Tata Chemicals, Company, Liquefied petroleum gas, Transport, Rail freight transport

COLUMBUS, Ind., Dec. 6, 2021 /PRNewswire/ --Grammer Logistics ( www.grammerlogistics.com ) ("Grammer" or the "Company"), a leading chemicals, industrial gases and hazardous materials transportation and logistics firm, announced today it is establishing a new Commercial Headquarters, located at 2001 Timberloch Place in The Woodlands, TX.

Key Points: 
  • COLUMBUS, Ind., Dec. 6, 2021 /PRNewswire/ --Grammer Logistics ( www.grammerlogistics.com ) ("Grammer" or the "Company"), a leading chemicals, industrial gases and hazardous materials transportation and logistics firm, announced today it is establishing a new Commercial Headquarters, located at 2001 Timberloch Place in The Woodlands, TX.
  • "We are very excited to open our commercial office in the heart of the chemicals capital of the world," stated Patrick Maher, Grammer's Chief Commercial Officer.
  • With more than 20 terminal locations across the United States, Grammer Logistics specializes in safe and reliable logistics solutions across various chemical market segments.
  • Grammer Logistics ( www.grammerlogistics.com ) is recognized as the premier provider of safe, dependable bulk hazardous chemicals transportation services in the United States.